INBX
Inhibrx Biosciences, Inc.
NASDAQ: INBX · HEALTHCARE · BIOTECHNOLOGY
$129.21
+3.52% today
Updated 2026-04-30
Market cap
$1.82B
P/E ratio
—
P/S ratio
1,402.52x
EPS (TTM)
$-9.04
Dividend yield
—
52W range
$11 – $155
Volume
0.3M
Inhibrx Biosciences, Inc. (INBX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-10,387.00%
ROE
-197.80%
ROA
-51.60%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2016 | $6.67M | $-8.27M | -154.87% | -182.18% | -124.03% |
| 2017 | $7.95M | $-19.44M | -220.88% | -248.15% | -244.55% |
| 2018 | $7.50M | $-31.16M | -346.05% | -393.51% | -415.51% |
| 2019 | $9.09M | $-51.40M | -426.86% | -480.74% | -565.27% |
| 2020 | $12.81M | $-75.64M | -473.82% | -526.57% | -590.54% |
| 2021 | $7.13M | $-81.77M | 62.27% | -1,074.58% | -1,147.62% |
| 2022 | $2.19M | $-145.23M | -4,926.73% | -5,890.37% | -6,625.27% |
| 2023 | $1.80M | $-241.36M | 33.83% | -12,178.94% | -13,408.94% |
| 2024 | $200000.00 | $1.69B | -1,042.50% | -165,724.00% | 843,786.00% |
| 2025 | $1.30M | $-140.06M | -91.00% | -10,386.54% | -10,773.46% |